CD4 and neoplasm: However, using RITs to deplete Tregs has strong side effects, as this treatment method affects CD4+CD25hi effector T cells, further weakening the body’s anti-tumor immunity and increasing the risk of the patient developing autoimmune diseases (72, 73).